hepatic steatosis

Pan-PPAR Agonist Lanifibranor: A Breakthrough in Improving Insulin Resistance and Hepatic Steatosis in T2D and MASLD Patients

By MedXY 09/20/2025

Lanifibranor, a pan-PPAR agonist, significantly reduces liver fat and improves insulin sensitivity at multiple tissue sites in type 2 diabetes patients with MASLD, offering a new therapeutic avenue to address underlying metabolic dysfunction.

Clinical Updates Wellness & Lifestyle

The Effect of Chitosan Supplementation on Liver Function, Hepatic Steatosis Predictors, and Metabolic Indicators in Adults with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial

By MedXY 08/08/2025

This clinical trial evaluates chitosan supplementation's impact on liver health and metabolic markers in adults with NAFLD, showing potential benefits alongside a low-calorie diet.

Clinical Updates Wellness & Lifestyle

Consecutive Fecal Microbiota Transplantation in MASLD: Insights from a Double-Blind Randomized Controlled Trial

By MedXY 08/07/2025

A double-blind RCT found that three consecutive fecal microbiota transplantations did not significantly improve hepatic steatosis or metabolic parameters in patients with MASLD, suggesting patient selection based on microbiota diversity may be crucial.